News
BerGenBio’s bemcentinib meets primary endpoint in first cohort of phase 2 NSCLC study in combination with Keytruda ®
Primary endpoint, Overall Response Rate, has been met in predominantly PD-L1 negative/low patientsSecondary endpoint, median…
Read MoreBerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BerGenBio to Present clinical data from Phase II trial with selective AXL inhibitor at 34th Annual SITC Meeting
Bergen, Norway, 02 October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
Bergen, Norway, 27 September 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference
Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer
Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159